ProKidney Corp.

ProKidney Corp.

生物技术研究

Winston-Salem,North Carolina 3,755 位关注者

A Step Closer to Potential Dialysis Prevention

关于我们

ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT? (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT? therapy. REACT? has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.

网站
www.prokidney.com
所属行业
生物技术研究
规模
51-200 人
总部
Winston-Salem,North Carolina
类型
上市公司

地点

  • 主要

    2000 Frontis Plaza Blvd

    250

    US,North Carolina,Winston-Salem,27103

    获取路线
  • 8020 Arco Corporate Dr

    400

    US,North Carolina,Raleigh,27617

    获取路线

ProKidney Corp.员工

动态

相似主页